 InflaRx NASDAQ: IFRX , a maker of anti-inflammatory therapeutics, is up 40 today after announcing its pursuing emergency-use authorization from the U.S. Food and Drug Administration for its Covid-19 treatment. Its Vilobelimab is the treatment InflaRx is targeting for FDA approval. 